Companies researching Lynparza (Olaparib)

Lynparza (olaparib) is a PARP‑inhibitor medication used as maintenance therapy for adults with advanced ovarian cancer that carries a BRCA mutation.

List of companies that research Lynparza (Olaparib)

This is sourced from job postings — companies only hire for what they actively use or plan to adopt · how we source this →

CompanyCountryIndustryEmployeesRevenueTechnologies
Country flag

United Kingdom

Pharmaceutical Manufacturing

79k

Lynparza (Olaparib)

Country flag

United Kingdom

Research Services

1.6k

$35M

Lynparza (Olaparib)

Country flag

United States

Pharmaceutical Manufacturing

41k

$10B

Lynparza (Olaparib)

Country flag

United Kingdom

Higher Education

11k

$716M

Lynparza (Olaparib)

Showing top companies out of 11 that research Lynparza (Olaparib). Get the full list on TheirStack.

Frequently asked questions